Thursday, August 8, 2013
Publication and contact
Angiopoietin 2 (ANG2;
Mouse studies suggest
inhibiting ANG2 could help treat sepsis. ANG2 is upregulated during sepsis.
In mice, endothelium-specific ANG2 overexpression increased microvascular disturbances,
hypotension and dilatory cardiomyopathy compared with normal expression. In a
mouse model for sepsis, two ANG2-targeting antibodies attenuated
microvascular and cardiac deterioration and decreased mortality compared with
a control antibody. Next steps include testing the antibodies in additional
mouse models and larger animal models of sepsis.
a bispecific mAb targeting VEGF
and ANG2, is in Phase I testing to treat solid tumors.
Inc. and Takeda
Pharmaceutical Co. Ltd. have trebananib,
a recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins,
in Phase III or earlier testing for various cancers.
Therapeutics plc has Atu111,
a small interfering RNA lipoplex against ANG2, in preclinical development to
At least three other companies have ANG2-targeting compounds in Phase I
testing or earlier to treat cancer or acute lung injury.
Published online Aug. 8, 2013
Antibodies patented by Roche
for treatment of cancer, vascular disease and retinopathies; licensing status
Ziegler, T. et al. J.
published online July 1, 2013;
Contact: Christian Kupatt, Klinikum Grosshadern of the
Ludwig Maximilians University, Munich, Germany
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]